Oxazolidinones, glycopeptides and cyclic lipopeptides;Oxazolidinonas, glucopéptidos y lipopéptidos cíclicos

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 27, Issue 4, 2009, Pages 236-246

  Pigrau, Carlos ^a   Almirante, Benito ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Oxazolidinones Linezolid Glycopeptides Vancomycin Teicoplanin Lipopeptides Daptomycin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CLINDAMYCIN; COTRIMOXAZOLE; CYCLOSPORIN; DALBAVANCIN; DAPTOMYCIN; DICLOXACILLIN; LINEZOLID; LIPOPEPTIDE; METICILLIN; ORITOVANCIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TELAVANCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANEMIA; BACTERIAL CELL WALL; BACTERICIDAL ACTIVITY; CENTRAL NERVOUS SYSTEM INFECTION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG CLEARANCE; DRUG EXCRETION; DRUG SAFETY; DRUG STRUCTURE; ENDOCARDITIS; FEVER; GASTROINTESTINAL SYMPTOM; GRAM POSITIVE BACTERIUM; HUMAN; KIDNEY FAILURE; LIVER FAILURE; MULTIDRUG RESISTANCE; MUSCLE DISEASE; MUSCLE TOXICITY; OSTEOMYELITIS; PNEUMONIA; PROTEIN SYNTHESIS; REVIEW; THROMBOCYTOPENIA;

EID: 67349153662     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2009.02.004     Document Type: Article

References (89)

1. C. Pigrau Oxazolidinonas y glucopéptidos antibiotics Enferm Infecc Microbiol Clin 21 2003 157 164
2. H.B. Fung , H.L. Kirschenbaum , and B.O. Oofeitimi Linezolid: an oxazolidinone antimicrobial agent Clin Ther 23 2001 356 391
3. M. Perry , and B. Jarvis Linezolid Drugs 61 2001 525 552
4. D.Y. Aksoy , and S. Umal New antimicrobial agents for the treatment of grampositive bacterial infections Clin Microbiol Infect 14 2008 411 420
5. E. Skripkin , T.S. McConnell , J. Devito , L. Lawrence , J.A. Ippolito , and E.M. Duffy R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance Antimicrob Agents Chemother 52 2008 3550 3557
6. R.J. Wallace , B.A. Brown-Elliot , S.C. Ward , C.J. Crist , L.B. Mann , and R.W. Wilson Activities of linezolid against rapidly growing mycobacteria Antimicrob Agents Chemother 45 2001 764 767
7. C. Pigrau , and J. Barberan Infecciones de piel y tejidos blandos causadas por grampositivos multirresistentes Enferm Infecc Microbiol Clin 26 Supl 2 2008 21 30
8. R. Manfredi Update on the appropiate use of linezolid in clinical practice Ther Clin Risk Manag 2 2006 455 464
9. E. Rubinstein , M.H. Kollef , and D. Nathwani Pneumonia caused by methicillin-resistant Staphylococcus aureus Clin Infect Dis 46 Suppl 5 2008 S378 S385
10. J. Cobo Papel de los grampositivos en las infecciones osteoarticulares Enferm Infecc Microbiol Clin 26 Supl 2 2008 31 43
11. R.P. Casaroli-Marano , L. Pelegrin , S. Ortiz , A. Adan , and B. Sanchez-Dalmau Infecciones oftalmológicas y linezolid Rev Esp Quimioter (Monogr) 1 2008 52 59
12. J.R. Lentino , M. Narita , and V.L. Yu New antimicrobial agents as therapy for resistant gram-positive cocci Eur J Clin Microbiol Infect Dis 27 2008 3 15
13. A. Manubens , J.R. Azanza , E. García-Quetglas , and B. Sadaba Perfil farmacológico de linezolid Rev Esp Quimioter (Monogr) 1 2008 2 9
14. F. Soriano Nuevos antibióticos frente a grampositivos: linezolid, tigeciclina, daptomicina, dalbavancina, telavancina, ceftobiprole Enferm Infecc Microbiol Clin 26 Supl 2 2008 13 30
15. J. Barberan , M.A. Menendez , J.R. Toral , and M.L. Porras Linezolid en las infecciones de la piel y partes blandas Rev Esp Quimioter (Monogr) 1 2008 26 30
16. B.A. Lipsky , K. Itani , and C. Norden Linezolid diabetic foot infections study group. Treating foot infections in diabetic patients: a randomised, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/ amoxicillin-clavulanate Clin Infect Dis. 38 2004 17 24
17. A.C. Kalil , S. Puumala , and J. Stoner Is linezolid superior to vancomycin for complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus? Antimicrob Agents Chemother 50 2006 1910
18. J. Weigelt , H.M.A. Kaafarani , K.M.F. Itani , and R.N. Swanson Linezolid erradicates MRSA better than vancomycin from surgical-site infections Am J Surg 188 2004 760 766
19. A.F. Shorr , M.J. Kunkel , and M. Kollef Linezolid versus vancomycin for Staphylococcus aureus bacteremia: pooled analysis of randomised studies J Antimicrob Chemother 56 2005 923 929
20. M.H. Wilcox , K.J. Tack , E. Bouza , D.L. Herr , B.R. Ruf , and M.M. Ijzerman Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study Clin Infect Dis 48 2009 203 212
21. R.G. Wunderink , J. Rello , S.K. Cammarata , R.V. Croos-Dabrera , and M.H. Kollef Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia Chest 124 2003 1789 1797
22. R.G. Wunderink , M.H. Mendelson , M.S. Somero , T.C. Fabian , A.K. May , and H. Bhattacharyya Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus Chest 134 2008 1200 1207
23. A. Soriano Experiencia clínica de linezolid en las infecciones osteoarticulares Rev Esp Quimioter (Monogr) 1 2008 60 67
24. Herruzo A, Rodríguez D, Pigrau C, Villar M, Pahissa A, Flores X. Effectiveness and tolerability of prolonged linezolid therapy for chronic osteomielitis. 26th European Bone Joint Society, Corfu, septiembre de 2007.
25. J.C. Dombrowski , and L.G. Winston Clinical failures of appropriately-treated methicillin-resistant Staphylococcus aureus infections J Infect 57 2008 110 115
26. P.A. Moise-Broder , G. Sakoulas , G.M. Eliopoulos , J.J. Schentag , A. Forrest , and R.C. Moellering Jr Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy Clin Infect Dis 38 2004 1700 1705
27. A. Soriano , F. Marco , J.A. Martínez , E. Pisos , M. Almela , and V.P. Dimova Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia Clin Infect Dis 46 2008 193 200
28. M.E. Falagas , K.G. Manta , F. Ntziora , and K.Z. Vardagas Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence J Antimicrob Chemother 58 2006 273 280
29. M. Billeter , M.J. Zervos , A.Y. Chen , J.R. Dalovisio , and Ch. Kurulularatne Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic Clin Infect Dis 46 2008 577 583
30. F. Gudiol , J.A. Aguado , A. Pascual , M. Pujol , B. Almirante , and J.M. Miro Documento de consenso sobre el tratamiento de la bacteriemia y la endocarditis causada por Staphylococcus aureus resistente a la meticilina Enferm Infecc Microbiol Clin 27 2009 105 115
31. B.P. Howden , P.B. Ward , P.G. Charles , T. Korman , A. Fuller , and P. Du Cros Treatment outcomes for serious infections caused by methicillin- resistant Staphylococcus aureus with reduced vancomycin susceptibility Clin Infec Dis 38 2004 521 528
32. P.A. Moise-Broder , C. Sakoulas , A. Forrest , and J.J. Schentag Vancomycin bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia Antimicrob Agents Chemother 51 2007 2582 2586
33. L.K. Hidayat , D.I. Hsu , R. Quist , K.A. Shriner , and Wong-Beringer High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity Arch Intern Med 66 2006 2138 2144
34. T.O. Lodise , N. Patel , A. Renaud-Mutart , E. Gorodecky , T. Fritsche , and R.N. Jones Larger vancomycin doses are associated with an increased incidence of nephrotoxicity Antimicrob Agents Chemother 52 2008 1330 1336
35. N. Markowitz , E.L. Quinn , and L.D. Saravolatz Trimethoprim- sulphamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection Ann Intern Med 117 1992 390 398
36. L.E. Jauregui , S. Babazadeh , E. Seltzer , L. Goldberg , D. Krievins , and M. Frederick Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections Clin Infect Dis 41 2005 1407 1415
37. R. Sauermann , M. Rothenburger , W. Graninger , and C. Joukhadar Daptomycin: a review 4 years after first approval Pharmacology 81 2008 79 91
38. J.N. Steenbergen , J. Alder , G.M. Thorne , and F.P. Tally Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections J Antimicrob Chemother 55 2005 283 288
39. P.I. Hair , and S.J. Keam Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia Drugs 67 2007 1483 1512
40. R. Wise , T. Gee , J.M. Andrews , B. Dvorchik , and G. Marshall Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers Antimicrob Agents Chemother 46 2002 31 33
41. P. Gerber , A. Stucki , F. Acosta , M. Cottagnoud , and P. Cottagnoud Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis J Antimicrob Chemother 57 2006 720 723
42. P. Cottagnoud , M. Pfister , F. Acosta , M. Cottagnoud , L. Flatz , and F. Kühn Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis Antimicrob Agents Chemother 48 2004 3928 3933
43. M.J. Rybak , E. Hershberger , T. Moldovan , and R.G. Grucz In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains Antimicrob Agents Chemother 44 2000 1062 1066
44. S.S. Richter , D.E. Kealey , C.T. Murray , K.P. Heilmann , S.L. Coffman , and G.V. Doern The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species J Antimicrob Chemother 52 2003 123 127
45. J.M. Streit , R.N. Jones , and H.S. Sader Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms J Antimicrob Chemother 53 2004 669 674
46. H.S. Sader , A.A. Watters , T.R. Fritsche , and R.N. Jones Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005) BMC Infect Dis 7 2007 29
47. D.J. Biedenbach , J.M. Bell , H.S. Sader , T.R. Fritsche , R.N. Jones , and J.D. Turnidge Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004) Int J Antimicrob Agents 30 2007 143 149
48. M. Castanheira , R.N. Jones , and H.S. Sader Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006) Diagn Microbiol Infect Dis 61 2008 235 239
49. C.T. Mascio , J.D. Alder , and J.A. Silverman Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells Antimicrob Agents Chemother 51 2007 4255 4260
50. K.L. LaPlante , and M.J. Rybak Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model Antimicrob Agents Chemother 48 2004 4665 4672
51. K.E. Piper , J.M. Steckelberg , and R. Patel In vitro activity of daptomycin against clinical isolates of Gram positive bacteria J Infect Chemother 11 2005 207 209
52. K.L. Tyrrell , D.M. Citron , Y.A. Warren , H.T. Fernandez , C.V. Merriam , and E.J. Goldstein In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes Antimicrob Agents Chemother. 50 2006 2728 2731
53. G.M. Thorne , and J. Alder Daptomycin: a novel lypopeptide antibiotic Clin Microbiol Newslett 24 2002 33 40
54. 2+ and albumin on these drugs Antimicrob Agents Chemother 35 1991 1710 1716
55. A.L. Baltch , W.J. Ritz , L.H. Bopp , P. Michelsen , and R.P. Smith Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular Staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages and in broth Antimicrob Agents Chemother 52 2008 1829 1833
56. S. Roveta , A. Marchese , and G.C. Schito Activity of daptomycin on biofilms produced on a plastic support by Staphylococcus spp Int J Antimicrob Agents 31 2008 321 328
57. I. Raad , H. Hanna , Y. Jiang , T. Dvorak , R. Reitzel , and G. Chaiban Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm Antimicrob Agents Chemother 51 2007 1656 1660
58. C.E. Edmiston Jr , M.P. Goheen , G.R. Seabrook , C.P. Johnson , B.D. Lewis , and K.R. Brown Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices Am J Surg 192 2006 344 354
59. F. Marco , C.G. De la Mària , Y. Armero , E. Amat , D. Soy , and A. Moreno Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus Antimicrob Agents Chemother 52 2008 2538 2543
60. H.W. Boucher , and G. Sakoulas Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus Clin Infect Dis 45 2007 601 608
61. A.A. Firsov , M.V. Smirnova , I.Y. Lubenko , S.N. Vostrov , Y.A. Portnoy , and S.H. Zinner Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model J Antimicrob Chemother 58 2006 1185 1192
62. L. Cui , E. Tominaga , H.M. Neoh , and K. Hiramatsu Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus Antimicrob Agents Chemother 50 2006 1079 1082
63. R.D. Arbeit , D. Maki , F.P. Tally , E. Campanaro , B.I. Eisenstein Daptomycin 98-01 and 99-01 Investigators The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections Clin Infect Dis 38 2004 1673 1681
64. B.A. Lipsky , and U. Stoutenburgh Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections J Antimicrob Chemother 55 2005 240 245
65. J.E. Krige , K. Lindfield , L. Friedrich , C. Otradovec , W.J. Martone , and D.E. Katz Effectiveness and duration of daptomycin therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infections Curr Med Res Opin 23 2007 2147 2156
66. R.C. Owens Jr , K.C. Lamp , L.V. Friedrich , and R. Russo Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin Am J Med 120 Suppl 1 2007 S6 S12
67. R.A. Seaton Daptomycin: rationale and role in the management of skin and soft tissue infections J Antimicrob Chemother 62 Suppl 3 2008 iii15 iii23
68. R. Cha , and M.J. Rybak Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations Diagn Microbiol Infect Dis 47 2003 539 546
69. K. Smith , G. Cobbs , R. Dill , D. Lyon , A. Graves , and K. Avent Daptomycin versus vancomycin treatment for Staphylococcus aureus bacteremia in a murine model Chemotherapy 36 1990 428 434
70. V.G. Fowler , H.W. Boucher , G.R. Corey , E. Abrutyn , A.W. Karchmer , and M.E. Rupp Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus N Engl J Med 355 2006 653 665
71. M.E. Falagas , K.P. Giannopoulou , F. Ntziora , and K.Z. Vardakas Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence J Antimicrob Chemother 60 2007 7 19
72. G. Sakoulas , Y. Golan , K.C. Lamp , L.V. Friedrich , and R. Russo Daptomycin in the treatment of bacteremia Am J Med 120 Suppl 1 2007 S21 S27
73. G. Sakoulas , G.M. Eliopoulos , J. Alder , and C.T. Eliopoulos Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 47 2003 1714 1718
74. G.P. Voorn , J. Kuyvenhoven , W.H. Goessens , W.C. Schmal-Bauer , P.H. Broeders , and J. Thompson Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin Antimicrob Agents Chemother 38 1994 487 493
75. L. Cantoni , M.P. Glauser , and J. Bille Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination Antimicrob Agents Chemother 34 1990 2348 2353
76. G.W. Kaatz , S.M. Seo , V.N. Reddy , E.M. Bailey , and M.J. Rybak Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis Antimicrob Agents Chemother 34 1990 2081 2085
77. S. Kennedy , and H.F. Chambers Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits Antimicrob Agents Chemother 33 1989 1522 1525
78. G.M. Eliopoulos , S. Willey , E. Reiszner , P.G. Spitzer , G. Caputo , and R.C. Moellering In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic Antimicrob Agents Chemother 30 1986 532 535
79. S.J. Rehm , H. Boucher , D. Levine , M. Campion , B.I. Eisenstein , and G.A. Vigliani Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates J Antimicrob Chemother 62 2008 1413 1421
80. D.P. Levine , and K.C. Lamp Daptomycin in the treatment of patients with infective endocarditis: experience from a registry Am J Med 120 Suppl 1 2007 S28 S33
81. ® Outcomes Registry and Experience (CORE) Int J Antimicrob Agents 2009 Feb 5 [Epub ahead of print]
82. M. Benvenuto , D.P. Benziger , S. Yankelev , and G. Vigliani Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers Antimicrob Agents Chemother 50 2006 3245 3249
83. K.C. Lamp , L.V. Friedrich , L. Mendez-Vigo , and R. Russo Clinical experience with daptomycin for the treatment of patients with osteomyelitis Am J Med 120 Suppl 1 2007 S13 S20
84. G.N. Forrest , B.J. Donovan , K.C. Lamp , and L.V. Friedrich Clinical experience with daptomycin for the treatment of patients with documented gram-positive septic arthritis Ann Pharmacother 42 2008 213 217
85. T. Lalani , H.W. Boucher , S.E. Cosgrove , V.G. Fowler , Z.A. Kanafani , and G.A. Vigliani Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia J Antimicrob Chemother 61 2008 177 182
86. N. Rao , and D.M. Regalla Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series Clin Orthop Relat Res 451 2006 34 37
87. M.E. Falagas , K.P. Giannopoulou , F. Ntziora , and P.J. Papagelopoulos Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence Int J Antimicrob Agents 30 2007 202 209
88. D.M. Livermore Future directions with daptomycin J Antimicrob Chemother 62 Suppl 3 2008 iii41 iii49
89. D.E. Katz , K.C. Lindfield , J.N. Steenbergen , D.P. Benziger , K.J. Blackerby , and A.G. Knapp A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria Int J Clin Pract 62 2008 1455 1464